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Abstract
BACKGROUND
The challenges for inflammatory bowel disease (IBD) diagnostics are to
discriminate it from gut conditions with similar symptoms such as irritable bowel
syndrome (IBS), to distinguish IBD subtypes, to predict disease progression, and
to establish the risk to develop colorectal cancer (CRC). Alterations in gut
microbiota have been proposed as a source of information to assist in IBD
diagnostics. Faecalibacterium prausnitzii (F. prausnitzii), its phylogroups, and
Escherichia coli (E. coli) have been reported as potential biomarkers, but their
performance in challenging IBD diagnostic situations remains elusive. We
hypothesize that bacterial biomarkers based in these species may help to
discriminate these conditions of complex diagnostics.
AIM
To evaluate the usefulness of indices calculated from the quantification of these
species as biomarkers to aid in IBD diagnostics.
METHODS
A retrospective study of 131 subjects (31 controls (H); 45 Crohn’s disease (CD), 25
ulcerative colitis (UC), 10 IBS, and 20 CRC patients) was performed to assess the
usefulness of bacterial biomarkers in biopsies. Further, the performance of
biomarkers in faeces was studied in 29 stool samples (19 CD, 10 UC). Relative
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abundances of total F. prausnitzii (FP), its phylogroups (PHGI and PHGII), and E.
coli (E) quantification were determined by qPCR. Loads were combined to
calculate the FP-E index, the PHGI–E index and the PHGII-E index. Biomarkers
accuracy to discriminate among conditions was measured by the area under the
receiver operating characteristic curve (AUC).
RESULTS
In biopsies, FP-E index was good for discriminating IBS from CD (AUC = 0.752)
while PHGII-E index was suitable for discriminating IBS from UC (AUC = 0.632).
The FP-E index would be the choice to discriminate IBD from CRC, especially
from all UC subtypes (AUC ≥ 0.875), regardless of the activity status of the
patient. Discrimination between UC patients that had the longest disease
duration and those with CRC featured slightly lower AUC values. Concerning
differentiation in IBD with shared location, PHGI-E index can establish
progression from proctitis and left-sided colitis to ulcerative pancolitis (AUC ≥
0.800). PHG I-E index analysis in tissue would be the choice to discriminate
within IBD subtypes of shared location (AUC ≥ 0.712), while in non-invasive
faecal samples FP or PHGI could be good indicators (AUC ≥ 0.833).
CONCLUSION
F. prausnitzii phylogroups combined with E. coli offer potential to discriminate
between IBD and CRC patients and can assist in IBD subtypes classification,
which may help in solving IBD diagnostics challenges.
Key words: Crohn’s disease; Ulcerative colitis; Inflammatory bowel disease; Diagnostic
tests; Faecalibacterium prausnitzii; Escherichia coli; Irritable bowel syndrome;
Colorectal cancer
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: This manuscript evaluates the usefulness of new indexes calculated from the
quantification of Faecalibacterium prausnitzii, its phylogroups, and Escherichia coli as
biomarkers to assist in challenges of inflammatory bowel disease diagnostics. Firstly,
discrimination between inflammatory bowel disease and other intestinal disorders was
tested. We present indices to distinguish colorectal cancer from inflammatory bowel
disease, especially from subjects with ulcerative colitis. This is of significance given the
association between chronic inflammation and the risk of colorectal cancer. In contrast,
the proposed indices featured limited performance for discriminating inflammatory
bowel disease from irritable bowel syndrome. Secondly, we approach if these
biomarkers would be useful to discriminate within inflammatory bowel disease subtypes.
We show here good biomarkers to differentiate inflammatory bowel disease subtypes of
shared disease location, which may assist in monitoring the risk of progression of the
inflamed area. Their application in non-invasive faecal samples is also demonstrated.
Citation: Lopez-Siles M, Aldeguer X, Sabat-Mir M, Serra-Pagès M, Duncan SH, Flint HJ,
Garcia-Gil LJ, Martinez-Medina M. Evaluation of bacterial biomarkers to aid in challenging
inflammatory bowel diseases diagnostics and subtype classification. World J Gastrointest




Inflammatory bowel diseases (IBD) are chronic inflammatory bowel disorders of
unknown aetiology that follow a course with periods of activity or flare-ups and
periods of remission[1-4]. Crohn’s disease (CD) and ulcerative colitis (UC) are the main
idiopathic  IBD[5-7].  Despite  these  disorders  differing  in  location,  histology,  and
distribution of  inflamed areas,  sometimes  they feature  overlapping clinical  and
pathological characteristics that hamper a distinct classification[8,9]. It is essential to
discriminate both entities to establish an appropriate treatment strategy[10]. Besides,
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there are other intestinal disorders, such as irritable bowel syndrome (IBS), that share
symptoms similar to those observed in the early stages of IBD thus increasing its
likelihood of misdiagnosis[11,12]. In contrast, chronic inflammation can lead to tumour
formation and promote colorectal cancer (CRC) development. It would, therefore, be
interesting to have a biomarker for IBD-progression to CRC, but currently, there is a
lack of tools to predict which cases may progress to CRC. Altogether, current IBD
diagnostics  challenges  are  to  discriminate  phenotype  variations  within  IBD
accurately, but also to differentiate IBD from other gut conditions with milder or
worsening phenotypes.
Given the absence of pathognomonic features, IBD diagnosis currently involves a
comprehensive  examination  of  the  patient  that  includes  clinical,  endoscopic,
radiologic, and histological criteria. Besides, as clinical manifestations of IBD are
unstable during the disease course, a long monitoring period is needed to classify the
disease  phenotype  accurately[11,15].  As  IBD  patients  feature  an  imbalanced  gut
microbial community in comparison to healthy subjects[16-25],  in the last years the
implementation of bacteria representative of this dysbiosis as biomarkers has been
started  to  be  explored  as  a  novel  strategy  to  support  IBD  diagnostics  and/or
prognostics[23,26-30].
We and others have pointed out that the abundance of faecal or mucosa-associated
Faecalibacterium prausnitzii  (F. prausnitzii) is a potential biomarker to discriminate
between gut disorders[23,26-30] Moreover, F. prausnitzii in conjunction with Escherichia coli
(E. coli) abundance (FP-E index) has been proven to be a better biomarker than total F.
prausnitzii alone[26,29]. Besides, the quantification of F. prausnitzii phylogroups I (PHG I)
and  II  (PHGII)  has  been  proposed  as  a  source  of  additional  information  to
discriminate between IBD subtypes. However, the usefulness of an index using the
quantification of the phylogroups in conjunction with E. coli remains to be explored.
Also, there is a lack of comparative studies from a methodological aspect that would
allow the establishment of the biomarker of choice.
It  is  against  this  background that  we examined six  options  for  biomarkers  (F.
prausnitzii, the two phylogroups or the combination of these three with E. coli) in a
cohort of non-IBD controls (H), IBS, IBD and CRC subjects, to (1) establish which
would be the best parameter to discriminate IBD patients from H and IBS subjects; (2)
determine which would be the best parameter to discriminate IBD from CRC patients;
and (3) identify which would be the most accurate parameter to discriminate within
IBD subtypes by location. We hypothesize that bacterial biomarkers based in these
species may be of help to discriminate these conditions of complex diagnostics.
MATERIALS AND METHODS
Patients, clinical data and sampling
In this study, data from two groups of subjects were included. Firstly, biomarker
performance  was  tested  in  biopsy  samples.  We  hypothesized  that  given  the
inflammatory nature of IBD, to look for biomarkers in the tissue would be strongly
associated with disease course. Secondly, the usefulness of selected biomarkers was
assessed in non-invasive samples (i.e., stools).
To  test  the  performance  of  the  mucosa-associated  bacterial  biomarkers,  a  re-
analysis  of  the data  from a Spanish cohort  including IBD,  IBS,  CRC,  and H was
performed (Table 1).  Subjects were consecutively recruited by the Department of
Gastroenterology at the Hospital Universitari Dr. Josep Trueta (Girona, Spain) and the
Gastroenterology Unit at the Hospital Santa Caterina (Institut d’Assistència Sanitària
of Girona, Salt, Spain) between May 2009 and November 2010. Patients were gender-
and age-matched, except CD patients who were significantly younger than those in
the H and IBS groups (P < 0.001) (Table 1). During routine endoscopy, up to three
biopsy samples per patient were taken from different locations along the gut (Table 2)
following standard procedures.
To  test  the  performance  of  bacterial  biomarkers  in  faecal  samples,  a  cohort
consisting  of  29  IBD  (19  CD  and  10  UC)  patients  was  recruited  by  the
Gastroenterology Services of  the Hospital  Universitari  Dr.  Josep Trueta (Girona,
Spain) between March 2014 and May 2015. Subjects were age- and gender-matched
for both the groups (Table 1). Participants were asked to collect a stool sample from
one bowel movement in a sterile faecal collection  container. Subjects brought samples
to the hospital, where they were stored at −80ºC until DNA extraction was performed.
To control bias between centres, patients with IBD were diagnosed according to
standard clinical, pathological, and endoscopic criteria and categorized according to
the Montreal classification. Patients with IBS were diagnosed according to Rome III
criteria (available at http://www.romecriteria.org/criteria/). CRC diagnosis was
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Age (mean ± SD,
yr)
48.1 ± 16.3 42.4 ± 11.4 40.1 ± 15.8 33.5 ± 11.1 58.6 ± 7.52 < 0.0014
Male, n (%) 16 (51.6) 2 (20.0) 16 (64.0) 26 (57.7) 14 (70.0%) 0.6056
Active, n (%) NA NA 20 (80.0) 28 (62.2) NA 0.1005
Treatment, n (%)2




NA NA 3 (12.0) 17 (37.8) NA






NA NA 6 (24.0) NA NA








Ileal-CD (L1) NA NA NA 19 (42.2) NA
Colonic-CD (L2) NA NA NA 11 (24.4) NA
Ileocolonic-CD
(L3)





n (patients) 10 19
Age (mean ± SD,
yr)
47.4 ± 18.3 43.5 ± 18.3 0.4294
Male, n (%) 5 (50.0) 10 (52.6) 0.8936
Active, n (%)2 1 (10) 7 (36.8) 0.1855
Treatment, n (%)2 NA NA 5 (50) 5 (26.3) NA














CD location, n (%)
Ileal-CD (L1) NA 10 (52.6) NA




1Controls consisted of subjects who underwent colonoscopy for different reasons: 9/31 rectal bleeding, 11/31 colorectal cancer familial history and 11/31
abdominal pain.
2Maximal disease extent at the time of sampling was available in 23/25 UC patients (cohort for biopsy samples), 4/10 UC patients (cohort for faecal
samples), 44/45 CD patients. Activity status in the cohort that provided faecal samples was available for 4/10 UC patients and 11/19 CD patients.
Treatment at sampling for the fecal sample’s cohort was recorded for 9/10 UC patients, and for biopsy sample’s cohort in 23/23 UC and 44/45 CD
participants.
3Groups were compared by non-parametric statistical tests, and P value ≤ 0.05 was considered significant.
4Kruskal-Wallis.
5 Mann-Whitney U test or
6χ2 test as required. IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome; CRC: Colorectal cancer; TNF: Tumour necrosis factor; NA: Not
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applicable.
established  by  colonoscopy  and  biopsy  examination,  and  none  of  the  subjects
underwent radiotherapy, chemotherapy or surgery. The control group consisted of
subjects  with  normal  colonoscopy  who  underwent  this  procedure  for  different
reasons (Table 1). Clinically relevant data of all participants, such as age, gender, and
disease activity at sampling, were collected (Table 1). Active CD were defined as those
with CDAI > 150 whereas active UC patients had a Mayo score > 3.
Individuals included in this study were > 18 years old, did not have any other
intestinal disease, and were not pregnant. Antibiotic treatment within the last month
prior to sample collection was the only exclusion criterion.  None of  the subjects
received probiotics before sample collection.
Sample treatment, DNA extraction, and qPCR assays
For biopsies,  sample treatment and DNA extraction were performed as reported
previously[26,27]. For faeces, 200-500 mg of faecal material were used for bacterial DNA
extraction  and  purification  with  the  NucleoSpin®  Soil  (Macherey-Nagel)  and
following the instructions from the manufacturer.
Previously designed and optimized 16S rRNA gene-targeted primers and probes
were  used  for  total  F.  prausnitzii[26],  phylogroups,  E.  coli  and  total  bacterial
quantification using quantitative polymerase chain reaction (qPCR).  Human cell
numbers were determined with the control kit RT-CKFT-18S (Eurogentec, Belgium)
according to the manufacturer’s instructions.
Amplification reactions were performed as described elsewhere[26,27,35,36]. In brief,
quantifications were performed in a total volume of 20 μL reactions containing: 1×
TaqMan Universal PCR Master Mix 2× (Applied Biosystems, Foster City, CA, United
States), 900 nmol/L of each primer, 300 nmol/L of each probe, and up to 50 ng of
genomic DNA template. Samples were run in duplicate in the same plate. For data
analysis,  the  mean  of  the  duplicate  quantifications  was  used.  Duplicates  were
considered valid if the standard deviation between quantification cycles (Cq) was
<0.34 (i.e., a difference of < 10% of the quantity was tolerated). Quantification controls
consisting  of  at  least  5  reactions  with  a  known  number  of  target  genes  were
performed to assess inter-run reproducibility. For samples with undetected values
during  quantification,  the  number  of  16S  rRNA  gene  copies  equivalent  to  the
detection  limit  of  each  reaction  was  used.  Inhibition  of  total  F.  prausnitzii
quantification was controlled by adding 103 copies of an internal amplification control
(IAC) template to each reaction. It was considered that there was no inhibition if the
obtained Cq was < 0.34 from those obtained when quantifying the IAC alone for any
of the replicates. A non-template control (consisting of a reaction without F. prausnitzii
DNA) and a non-amplification control (which did not contain any DNA template,
either bacterial or IAC) were also included in each run. Negative controls resulted in
undetectable Cq values in all cases.
All  quantitative  PCRs  were  performed  using  a  7500  Real  Time  PCR  system
(Applied Biosystems). The thermal profile was: a first step at 50 ºC during 2 min for
amperase treatment,  followed by a  95 ºC hold for  10 min to  denature DNA and
activate  Ampli-Taq  Gold  polymerase,  and  a  further  40  cycles  consisting  of  a
denaturation step at 95 ºC for 15 seconds followed by an annealing and extension step
at 60 ºC (or at 64ºC for phylogroups quantification) for 1 min. Data were collected and
analysed using the 7500 SDS system software version 1.4 (Applied Biosystems). All
quantifications were performed under average PCR efficiencies of 89.51 ± 7.06%.
Sample size, data normalization and statistical analysis
The sample size was defined after the number of patients analysed in similar studies
of bacterial abundance in subjects suffering of these conditions[20,22,26,28].
Relative abundances of total F. prausnitzii, phylogroups, and E. coli copy numbers
were calculated by normalizing each species load for the total bacterial 16S rRNA
gene copies. Data are given as the log10 of the ratio between 16S rRNA gene copies of
the target microorganism and millions of total bacterial 16S rRNA genes detected in
the same sample.
For biopsies,  species relative abundances were combined to calculate the FP-E
index as previously reported[26]. Similarly, the PHGI–E index and the PHGII-E index
were calculated as follows:
PHGI-E index = [log10 (PHGI/Hc)- log10 (E/Hc)]/ [log10 (TB/Hc)]
PHGII-E index = [log10 (PHGII/Hc)- log10 (E/Hc)]/ [log10 (TB/Hc)]
Being PHGI and PHGII the 16S rRNA gene copies of F. prausnitzii phylogroup I or
II respectively; E the 16S rRNA gene copies of E. coli; Hc a million of human cells; and
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Table 2  Biopsy samples by conditions and locations
No. Patients
No. biopsies
Terminal ileum Transverse colon Rectum Unknown region Total
H 31 14 24 10 0 48
IBS 10 1 3 3 12 19
CRC 20 3 17 0 20
UC 25 11 23 16 0 50
Location
Ulcerative proctitis (E1) 6 4 5 5 0 14
Distal UC (E2) 11 3 11 8 0 22
Extensive UC or ulcerative pancolitis (E3) 6 3 6 1 0 10
CD 45 16 31 16 0 63
Location
Ileal-CD (L1) 19 5 13 7 0 25
Colonic-CD (L2) 11 6 7 4 0 17
Ileocolonic-CD (L3) 14 4 10 4 0 18
H: Healthy controls; IBS: Irritable bowel syndrome; CRC: Colorectal cancer; UC: Ulcerative colitis; CD: Crohn’s disease.
TB a million of 16S rRNA gene copies of total bacteria.
For faecal samples, as no Hc quantification was performed to normalize sample
size, indexes were calculated as:
FP-E index = log10 (total F. prausnitzii/E)
PHGI-E index = log10 (PHGI/E)
PHGII-E index = log10 (PHGII/E)
Differences in categorical variables such as gender were assessed by the χ2 test. For
continuous variables such as age or biomarkers load, data normality was assessed
through the KolmogorovâSmirnov test. The non-parametric Kruskal-Wallis test was
used  to  asses  differences  in  variables  with  more  than  two  categories,  such  as
diagnostics, and CD or UC disease location. Pairwise comparisons of subcategories of
these variables were analysed using a Mann-Whitney U test. This test was also used
to compare, within a subgroup of patients, variables with two categories.
The receiver operating characteristic curve analysis, a plot of the true-positive rate
(sensitivity) versus false-positive rate (1-specificity),  was applied to establish the
usefulness of F. prausnitzii, along with each phylogroup, alone or in conjunction to E.
coli counts (FP-E index, PHGI-E index, and PHGII-E index) to distinguish different
intestinal conditions. The accuracy of discrimination was measured by the area under
the receiver operating characteristic curve (AUC). An AUC approaching 1 indicates
that the test is highly sensitive and highly specific, whereas an AUC approaching 0.5
indicates that  the test  is  neither sensitive nor specific.  For the best  cut-off  value,
specificity and sensitivity were established.
All the statistical analyses were performed using the SPSS 15.0 statistical package
(LEAD Technologies, Inc.). Significance levels were established for P values ≤ 0.05.
The statistical methods of this study were reviewed by MSc. Oliver Valero Coppin
from the Statistical Service at the Universitat Autònoma de Barcelona.
RESULTS
Discrimination of IBD from H and IBS
When considering all biopsy samples (Figure 1A), PHGI quantification was the most
discriminative biomarker between H and IBD patients (AUC > 0.75).  This can be
attributed to higher load of PHGI in H in comparison to the other groups of subjects
(Supplementary Table 1). Notably, discrimination was especially good between H and
subjects with CD, which achieved 73% specificity and 91% sensitivity at the best cut-
off  value (Log10[16S rRNA phylogroup I/106  16S rRNA total bacteria] =2.3).  This
discrimination was particularly accurate when analysing ileal samples (AUC > 0.9)
(Figure 1B). Besides, discrimination between H and IBD subjects achieved greater
AUC values when considering only active IBD patients (Figure 1C). However, the
discrimination was still good (AUC > 0.75) when taking into account only those with
inactive disease. Therefore, our results support PHGI as an indicator of healthy gut
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status.
Regarding discrimination between IBD and IBS patients,  different  biomarkers
performed best to distinguish IBS from UC or CD. When pooling all biopsy samples
(Figure  1A),  PHGII-E  index  was  suitable  to  discriminate  IBS  from  UC.  This
discrimination was excellent when considering ileal or rectal biopsies and suitable for
colonic biopsies analyses (Figure 1B). It is of note that the PHGII-E index allowed
good discrimination between these two conditions, even in the inactive cohort of
patients (Figure 1C). In contrast, FP-E index was good for discriminating IBS from CD
when pooling all samples, although this was not sustained for all sampled locations,
probably due to the effect of the location of inflammation in CD. In contrast, FP was
the best biomarker to discriminate IBS and CD in colonic and rectal samples, whereas
PHGI counts discriminated best at the ileum (Figure 1B). This biomarker was good to
discriminate IBS from active CD patients, whereas the PHGII-E index provided the
best  discrimination  between  IBS  and  inactive  CD.  Overall,  to  select  a  general
biomarker to discriminate IBS from IBD, useful in all kinds of samples and conditions
was challenging. However, FP could be an interesting candidate as performed in the
suitable-excellent AUC range for all comparisons, regardless of the intestinal region
selected for analysis.
Discrimination between IBD with colonic inflammation and CRC
In  general,  the  FP-E  index  was  the  most  discriminatory  between  CRC and  IBD
patients when taking into account all biopsy samples together (Figure 2A), because
lower  FP-E values  were  associated with  CRC subjects  (Supplementary  Table  1).
Notably, discrimination was especially good between CRC and UC patients, which
achieved 85% specificity and 94% of sensitivity at the best cut-off value (FP-E index=
0.009). This discrimination was excellent between CRC and patients with ulcerative
proctitis (E1) and ulcerative pancolitis (E3) with 85% specificity and 100% sensitivity,
while for patients with extensive UC (E2) sensitivity was reduced to 86% with the
same specificity rate. Although good discrimination was achieved (AUC > 0.870) we
observed that discern between E2 patients and those with CRC featured slightly lower
AUC values, and in turn, these groups of patients had the longest disease duration
(mean years of disease duration ± SD by UC subtype was: E1 = 0.93 ± 1.69; E2 = 7.10 ±
4.27; E3 = 2.63 ± 2.20.
In addition, this excellent discrimination was sustained regardless of the activity
status of the patients. Regarding the location of sample (Figure 2B), for our particular
cohort,  colonic  biopsies  were  the  most  discriminatory  between  CRC  and  those
patients with E1 and E3, although good separation of groups was also achieved with
rectal samples. In turn, rectal samples performed better to discriminate between E2
subjects and those with CRC.
The FP-E index was also suitable to classify CRC patients and those with CD of
colonic  location  (i.e.,  C-CD  and  IC-CD).  Interestingly,  better  AUC  values  were
obtained for PHGI and when considering rectal samples alone, which needs further
confirmation given the low number of  samples  analysed at  this  location for  CD
patients.
Discrimination within IBD with shared location
Biomarkers analyses in biopsy samples: The FP-E index was the best biomarker to
differentiate UC from CD patients considering all locations (Figure 3A), given that UC
patients had higher FP-E index values than CD patients (Supplementary Table 1).
However, no consensus could be reached about the biomarker that performed best
when comparing IBD subtypes with shared location of the inflammation. PHGI-E
index was good to differentiate E1 and E2 from E3, particularly in ileal samples (AUC
≥ 0.875) although suitable discrimination was also obtained when analysing colonic
biopsies. In contrast, the PHGII-E index was the most accurate to discriminate C-CD
from all UC locations when considering all samples together, and this was sustained
in colonic samples (Figure 3B).
As regards discrimination between CD locations, in general, all the biomarkers
showed AUC ≤ 0.75 except for the PHGII-E index in ileal samples, which allowed for
good discrimination between IC-CD from both C-CD and I-CD.
Interestingly, when considering only active patients, the PHGI-E index was the
most  discriminatory  for  all  the  comparisons  when  pooling  samples,  and  when
considering  only  those  from  the  ileum  and  colon.  Except  for  CD  with  ileal
involvement, also suitable discrimination was obtained with the PHGI-E index from
rectal samples. Analyses in inactive patients are not shown because, in most cases,
they  could  not  be  conducted  given  the  low  number  of  samples  with  these
characteristics when separating by IBD subtype.
Biomarkers analyses in faecal samples: Analyses of IBD faecal samples showed that
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Figure 1
Figure 1  Usefulness of Faecalibacterium prausnitzii, its phylogroups (PHGI and PHGII) and their index in
conjunction to Escherichia coli to discriminate between milder gut conditions [Healthy controls (H) and
irritable bowel syndrome] and inflammatory bowel disease (ulcerative colitis and Crohn’s disease) by pooling
all biopsy samples together (A), by location of sampling (B) and by activity status (C). Best area under the
receiver operating characteristic curve (AUC) values for each comparison are shown. FP: Faecalibacterium
prausnitzii; UC: Ulcerative colitis; CD: Crohn’s disease; IBS: Irritable bowel syndrome.
the most suitable biomarker to discriminate between UC and CD conditions was
PHGI (Figure 3C), whose load was higher in the former, regardless of the disease
extent (Supplementary Table 2). This biomarker was different from that found in
biopsies, and the AUC was 1.4 times lower than that obtained in tissue samples.
In contrast,  better  AUC values were achieved in faecal  samples for  PHGI and
PHGI-E compared to those in biopsies to discriminate C-CD from E2, E3 and IC-CD,
although corroboration by engaging more C-CD subjects is needed. It is of note that
the results obtained for FP as a biomarker to distinguish IC-CD from I-CD, which
substantially improved the biopsy results.
DISCUSSION
Quantification of bacterial biomarkers may be a valuable tool to assist in the diagnosis
of intestinal disorders. In this work, we explored the usefulness of two species (E. coli
and  F.  prausnitzii),  extensively  reported  as  dysbiosis  representatives  of
IBD[16,18-20,22,23,26-30], to discriminate between different gastrointestinal disorders.
Firstly,  we explored whether or  not  these bacterial  biomarkers  could assist  in
discriminating IBD from IBS, where symptoms can be similar at early stages of the
disease. It was observed that a general biomarker to discriminate IBS from IBD could
not be established, and therefore two biomarkers should be used. While FP-E index
allowed  discrimination  between  IBS  and  CD,  PHGII-E  index  was  the  most
appropriate to discriminate between IBS and UC. Our cohort of IBS patients was
limited  and  not  classified  by  IBS  subtypes.  As  differences  in  gut  microbiota
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Figure 2
Figure 2  Usefulness of Faecalibacterium prausnitzii, its phylogroups (PHGI and PHGII) and their index in conjunction to Escherichia coli to discriminate
inflammatory bowel disease with colon inflammation and colorectal cancer by pooling all biopsy samples together (A) and by location of sampling (B). For
the best biomarker, results depicted by activity status of the patients are shown in the right panels. Best area under the receiver operating characteristic curve (AUC)
values for each comparison are shown. : AUC not calculated (comparisons with one empty group of subjects). E1: Ulcerative proctitis; E2: Distal UC; E3: Extensive
UC or ulcerative pancolitis; C-CD: Colonic-CD; IC-CD: Ileocolonic-CD; FP: Faecalibacterium prausnitzii; UC: Ulcerative colitis; CRC: Colorectal cancer; CD: Crohn’s
disease.
composition have been found between patients with diarrhoea-predominant IBS and
those with constipation-predominant IBS[37], we propose that in further studies aiming
to define a biomarker between IBS and IBD, phenotype should be taken into account.
Besides, the inclusion of newly diagnosed patients would be of interest to establish
whether these biomarkers would be of assistance to discriminate between conditions
at an early stage of the disease, particularly when symptoms are overlapping.
Secondly, as there is an association between IBD (especially those involving colonic
inflammation) and risk of CRC[13,38], the usefulness of the six biomarkers to tell apart
CRC and IBD patients  with  colonic  inflammation  was  explored.  Among the  six
options  of  biomarkers  considered,  the  FP-E  index  was  the  most  discriminatory
between CRC and IBD patients, especially from UC, regardless of the activity status of
the patient and irrespective of whether colonic or rectal samples were used. This
observation is of particular relevance because it has been demonstrated that the extent
and duration of the disease increase the risk of patients with UC developing CRC.
Future follow-up studies to establish if this index would be useful to predict the risk
of CRC development associated with IBD are needed. In contrast, discrimination for
CD patients was somewhat limited. Therefore it would be of interest to determine if
the combination of F. prausnitzii or its phylogroups with other representatives of CRC
dysbiosis enriched in CRC patients[39,40] such as some phylotypes related to Bacteroides,
P. stomatios or G. morbillorum could provide a clearer diagnostic test.
Finally,  the usefulness of  these biomarkers to discriminate IBD subtypes with
shared  location  of  inflammation  was  assessed.  The  PHGI-E  index  was  a  good
parameter to discriminate UC subtypes, which is of interest for clinicians to monitor
the risk of progression of the inflamed area. From our data, this index allowed the
best  discrimination within  UC subtypes  with  active  disease  in  ileal  and colonic
samples. However, a deeper analysis to decipher which sample is the best to analyse
is required, as in our study, not all the subjects provided samples from all locations,
and interindividual  variability  may be  affecting  our  observations.  Also,  further
confirmation is required concerning inactive patients since our cohort was limited.
In contrast, we have observed that PHGII load, in conjunction with E. coli counts,
can distinguish with suitable accuracy between all UC patients regardless of their
disease subtypes and patients with colonic CD (C-CD). The capacity to discriminate
between patients with C-CD and E3 is noteworthy because inflammation in these two
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Figure 3
Figure 3  Usefulness of Faecalibacterium prausnitzii, its phylogroups (PHGI and PHGII) and their index in conjunction to Escherichia coli to discriminate
within inflammatory bowel disease with colon inflammation taking into account all biopsy samples together (A), by location of sampling (B) and faeces (C).
For tissue samples, selected results for PHGI- Escherichia coli of active patients are shown in the right panels. Data for inactive patients is not included because of the
small cohort engaged. Best area under the receiver operating characteristic curve (AUC) values for each comparison are shown. UC: Ulcerative colitis; CD: Crohn’s
disease; E1: Ulcerative proctitis; E2: Distal UC; E3: Extensive UC or ulcerative pancolitis; C-CD: Colonic-CD; IC-CD: Ileocolonic-CD; FP: Faecalibacterium prausnitzii;
UC: Ulcerative colitis; CRC: Colorectal cancer; CD: Crohn’s disease.
disorders  affects  a  wide  area  of  the  colon  and  may  present  similar  clinical
manifestations, thus hampering a clear classification. Due to differences in treatment
and management between UC and CD[10] it is extremely important to discriminate
between these two entities accurately.
The best discrimination for CD vs UC was obtained for patients without shared
inflamed area (data not shown),  but the discrimination needs to be improved to
differentiate  IBDs  with  shared  disease  location,  particularly  within  CD.  The
combination of F. prausnitzii  or its phylogroups with other representatives of IBD
dysbiosis  may  be  a  way  to  improve  discrimination  between  IBD  subtypes.  For
instance, depletion of Roseburia hominis has been reported as representative of UC
dysbiosis, while the depletion of Ruminococcus gnavus and Ruminococcus  torques, with
a concomitant increase in Dialister invisus  or Bifidobacterium adolescentis  have been
reported as signatures of CD dysbiosis[16,18]. In addition, the identification of novel
species whose abundance differs between IBD subtypes sharing the inflamed location
may be of assistance in this regard.
Overall,  we observed that  the FP-E index would be the selected biomarker  to
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discriminate IBD from CRC while PHG I-E index would be the choice to discriminate
within IBD subtypes, and yet no general biomarker of preference could be established
to discriminate IBS from IBD. PHGII-E index would be suitable to tell apart IBS and
UC patients, whereas the FP-E index could be of assistance to discriminate between
IBS and CD although further confirmation on its usefulness for inactive patients is
required. It has been reported that active CD and UC can be specifically diagnosed
monitoring the faecal bacterial  community in conjunction with leukocyte counts.
Although in  this  previous  study location  of  disease  has  not  been  considered,  it
demonstrates that serologic biomarkers may be a source of additional information. A
recent study suggested that  anti-E. coli,  anti-Fusobacterium nucleatum,  and anti-F.
prausnitzii antibodies did not possess diagnostic value for CD or UC,. However, it
would be worth testing if discrimination between gut conditions is enhanced when
these bacterial  indicators are combined with other previously reported serologic
biomarkers of intestinal disease [such as calprotectin, lactoferrin, C-reactive protein,
Perinuclear  Anti-Neutrophil  Cytoplasmic  Antibodies  (p-ANCA),  and  Anti-
Saccharomyces cerevisiae antibodies (ASCA)].
In  order  to  establish  if  the  proposed  indices  are  suitable  for  discriminating
conditions in less invasive samples, data from the quantification of these species in
faeces of IBD subjects was used. We restricted the proof of concept to IBD subjects as
these are the conditions more similar in clinical traits and therefore more difficult to
discriminate. Our results allowed to demonstrate that, despite our initial selection of
biomarkers was based in tissue samples, they are also valuable in faeces. However,
differences in which biomarkers performed the best were found. These differences
could be because the cohorts used for faecal and biopsy analyses involved different
subjects or may reflect the fact that gut microbiota composition is different between
faeces and biopsies. Thus, in the future, if biomarkers are selected from tissue, it is
crucial  to test  performance in faecal  samples,  ideally including the two kinds of
samples from the same subject. We have observed that whereas quantification of E.
coli in biopsies improved discrimination, the role in improving discrimination when
faecal samples are used remained more limited.
On the one hand, this may be explained by the fact that this species may be directly
involved in host-interaction during diseases. On the other hand, this information
leads us to hypothesize that for future applications, other biomarkers selected from
faecal samples analysis could also be included. Concerning F. prausnitzii, the observed
differences on which subpopulation should be used as a biomarker, may be related to
the distribution of phylogroups along with the gastrointestinal tract, each one with
specific metabolic features[43,44].
To robustly validate our observations would require a larger cohort of completely
independent patients, including volunteers from different ethnicities, to test these
biomarkers as a tool for gut disease diagnostics. Moreover, it would be of interest to
test whether F. prausnitzii or its phylogroups, in conjunction with E. coli as biomarkers
could discriminate other intestinal disorders within IBD such as indeterminate colitis,




Currently, inflammatory bowel diseases (IBD) diagnostics features several challenges mainly
related to its accurate differentiation  from other disease with similar symptoms. In the last years,
some studies have shown that the abundance of Faecalibacterium prausnitzii (F. prausnitzii) is a
potential biomarker to discriminate between gut disorders. This species load in conjunction with
Escherichia coli (E. coli) abundance (F-E index) has been proven to be a better biomarker than total
F. prausnitzii alone. Besides, the quantification of F. prausnitzii phylogroup I and phylogroup II
has been proposed as a source of additional information to discriminate within IBD. However,
the usefulness of an index including the quantification of the phylogroups in conjunction with E.
coli remains to be explored, and also its applicability to tell apart these conditions from other gut
disorders with milder or worsen phenotypes.
Research motivation
Currently, IBD diagnosis involves a comprehensive examination of the patient that includes
clinical, endoscopic, radiologic, and histological criteria. In addition, as clinical manifestations of
IBD are unstable during the disease course, a long monitoring period is needed to classify the
disease phenotype accurately. As IBD patients feature an imbalanced gut microbial community
in comparison to healthy subjects, in the last years the implementation of bacteria representative
of this dysbiosis as biomarkers has been started to be explored as a novel strategy to support IBD
diagnostics and/or prognostics.
Research objectives
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The main objective of this study was to evaluate six options of bacterial biomarkers in terms of
their capability to discriminate IBD from other gut disorders and within IBD subtypes.
Research methods
Adult males and females undergoing routine colonoscopy at the Hospital Dr. Josep Trueta and
Parc Hospitalari Martí i Julià in Girona (Spain) were asked to participate, providing either biopsy
and/or faecal samples. Subjects included healthy controls as well as patients with IBD, CRC or
irritable bowel syndrome (IBS). Genomic DNA extracts of samples were used to assess the load
of bacterial markers candidates (total F. prausnitzii, phylogroup I and II of this species and E. coli)
by qPCR using specific  primers previously reported.  Relative abundances to total  Bacteria
present  in  the  sample,  and  indices  combining  F.  prausnitzii  and  E.  coli  were  calculated.
Biomarkers accuracy to discriminate conditions was measured by the area under the receiver
operating characteristic curve (AUC). To the best of our knowledge, this is the first study that
tests combination of F. prausnitzii phylogroups and E. coli application to assist in discriminating
challenging IBD diagnostic conditions, compares their performance with previously reported
biomarkers and further corroborates results in non-invasive samples.
Research results
This study reveals that the F-E index would be the choice to discriminate IBD from colorectal
cancer (CRC), especially from ulcerative colitis (UC), regardless of the activity status of the
patient  and irrespectively  if  a  colonic  or  a  rectal  sample  was  used.  This  observation  is  of
particular relevance because there is an association between IBD (especially those involving
colonic inflammation) and the risk of CRC. Besides, we have observed that PHG I-E index is a
good parameter to differentiate pancolitis from other UC subtypes,  which is of interest for
clinicians to  monitor  risk of  progression of  the inflamed area.  The application of  bacterial
biomarkers in feces is also demonstrated, which is a non-invasive method and may represent a
step forward to implement these biomarkers in clinical practice to support IBD diagnostics.
Research conclusions
This study corroborates that F. prausnitzii combined with E. coli can help to discriminate within
IBD subtypes both in tissue and fecal samples, as well as offer potential to differentiate IBD and
CRC patients.  Use of biopsy samples presented better performance, but we confirmed that
suitable results in fecal samples were shown too. The comparison of the performance of new
indices with those previously reported in the literature has allowed establishing the biomarker of
choice to select  depending on the conditions to discriminate.  From these comparisons,  we
hypothesize  that  given  the  complexity  of  the  disease  in  terms  of  multiple  subtypes  and
phenotypes during the disease course, it would be complicated the establishment of a universal
biomarker using only two species and total microbiota composition could be a more informative
approximation in this regard. However, given the outcome obtained only with the biomarkers
evaluated here, we envisage that implementation of bacterial load assessment in clinical routine
may ease IBD diagnostics in the future, for example for initial screening.
Research perspectives
This study contributes to providing evidence that bacterial biomarkers assessment may help in
solving intestinal disorders diagnostic challenges. Because differences in performance were
observed between tissue and faecal samples, attention should be paid to this issue in similar
studies. Future directions of research could assess if discrimination between gut conditions is
enhanced  when  these  bacterial  indicators  are  combined  with  other  bacterial  or  serologic
biomarkers of intestinal disease. Also, validation in a larger cohort of completely independent
patients, including volunteers from different regions would be required to define a tool with
worldwide application in clinical routine.
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